TAGS: Sealants
Ethicon in partnership with Grifols has launched VISTASEAL Fibrin Sealant (Human) to help surgeons manage disruptive bleeding during surgery. The collaboration combines Ethicon’s expertise in developing device technology with Grifols’ ability to produce critical plasma-based therapies.
Sustain Hemostasis by Forming Rapid Clots
VISTASEAL Fibrin Sealant (Human) contains a combination of fibrinogen and thrombin, clotting proteins found in human plasma. The product when applied to the bleeding site, forms a rapid, adherent, and durable clot and sustain hemostasis (stoppage of bleeding), even in high-risk patients. VISTASEAL was associated with a lower overall hemostatic retreatment rate (0.9%-7.8%) compared to standard treatments (8.0%-16.7%).
“
Surgical patients often present with multiple risk factors such as coagulopathies, uncontrolled diabetes, renal or liver failure or are taking anticoagulants or chronic antiplatelet therapies that may interfere with the body’s natural ability to form a clot, which increases the risk of surgical bleeding,” said David Kwon, MD, FACS, Director of Surgical Oncology, Henry Ford Hospital. “
VISTASEAL has the potential to offer a rapid, adherent, durable clot even in my most demanding cases” added Kwon.
Exclusively Designed Spray Sealant
The fibrin sealant exclusively designed to be sprayed without gas in both open and minimally invasive procedures, and it comes in pre-filled syringes. This eliminates some of the steps required for set-up with gas and may save valuable time in the operating room. The VISTASEAL Dual Applicator tip is also uniquely malleable enabling access to difficult anatomy and enhanced spray control.
Throughout a surgical procedure, bleeding must be controlled not only to provide a clear view of the operative site, but also to prevent the adverse clinical outcomes associated with blood loss. An estimated 32 to 68 % of cases in open surgery procedures experience disruptive bleeding events.
Advances in Surgery Care
The sealant is indicated as an adjunct to hemostasis for mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature, and cautery) are ineffective or impractical. The product is effective in patients treated with heparin (blood thinner).
“
VISTASEAL is the latest addition to our broad portfolio of primary and adjunctive hemostat solutions that address the growing and wide-ranging challenges surgeons face in managing bleeding,” said Oray Boston, President, Global Biosurgery, Ethicon. “
We will continuously aim to advance the standard of care in surgery to better serve health care professionals and improve outcomes for patients” added Boston.
Source: Ethicon